STERIS (NYSE:STE) CEO Sells $655,510.56 in Stock

STERIS plc (NYSE:STE) CEO Daniel Carestio sold 3,054 shares of STERIS stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $214.64, for a total transaction of $655,510.56. Following the sale, the chief executive officer owned 65,021 shares of the company’s stock, valued at approximately $13,956,107.44. This represents a 4.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

STERIS Stock Down 2.4%

Shares of NYSE:STE opened at $207.71 on Thursday. STERIS plc has a one year low of $195.14 and a one year high of $269.44. The company has a 50 day moving average of $216.60 and a 200-day moving average of $237.99. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. The stock has a market cap of $20.27 billion, a price-to-earnings ratio of 26.19 and a beta of 0.93.

STERIS (NYSE:STE) last issued its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the prior year, the firm earned $2.74 EPS. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, sell-side analysts forecast that STERIS plc will post 11.18 earnings per share for the current year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Investors of record on Monday, June 8th will be issued a dividend of $0.63 per share. The ex-dividend date is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. STERIS’s payout ratio is currently 31.78%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Trust Co. of Vermont lifted its stake in STERIS by 30.2% in the fourth quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 38 shares in the last quarter. Bailard Inc. lifted its stake in STERIS by 3.5% in the fourth quarter. Bailard Inc. now owns 1,118 shares of the medical equipment provider’s stock valued at $283,000 after buying an additional 38 shares in the last quarter. Magnolia Capital Advisors LLC lifted its stake in STERIS by 1.2% in the third quarter. Magnolia Capital Advisors LLC now owns 3,588 shares of the medical equipment provider’s stock valued at $888,000 after buying an additional 41 shares in the last quarter. Colonial Trust Co SC lifted its stake in STERIS by 0.3% in the third quarter. Colonial Trust Co SC now owns 12,329 shares of the medical equipment provider’s stock valued at $3,051,000 after buying an additional 42 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its stake in STERIS by 34.9% in the second quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 45 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Piper Sandler restated an “overweight” rating and set a $270.00 price objective on shares of STERIS in a report on Thursday, May 21st. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 6th. Weiss Ratings cut shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Finally, KeyCorp decreased their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and an average price target of $278.00.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.